Category: Joint ventures/collaborations
-
23andMe, Pfizer Partner on Bowel Disease Genetics
12 August 2014. The pharmaceutical company Pfizer and personal genetics company 23andMe in Mountain View, California are researching genetic factors associated with inflammatory bowel disease, for which Pfizer is testing several treatments. Financial aspects of the collaboration were not disclosed. Inflammatory bowel disease is the name given to disorders of the digestive tract, such as…
-
Licensing Deal Combines Genomics, Placenta Stem Cells
11 August 2014. A new licensing agreement will make available research by Celgene Cellular Therapeutics on stem cells from the placenta to Human Longevity Inc., a company specializing in genomics for age-related disorders. Financial aspects of the agreement were not disclosed, but as part of the deal, Celgene is expected to make an equity investment…
-
Efficient Sequencing Method Devised to ID Cells, Biomarkers
6 August 2014. Researchers at University of California in San Francisco and Fluidigm Corp. in South San Francisco developed a more efficient process for analyzing genetic material, still revealing cell types and biomarkers that previously required more in-depth analysis. The team led by Arnold Kriegstein, director of UCSF’s regeneration medicine and stem cell center, and…
-
Consortium to Develop Common Neuroscience Data Format
4 August 2014. A coalition of research institutes and universities working in neuroscience are constructing a common format for sharing data about the brain to make emerging databases more useful to researchers. The Neurodata Without Borders project is an initiative of Allen Institute for Brain Science, California Institute of Technology, New York University School of…
-
Allied Minds, Bristol-Myers Squibb Form Life Science Venture
4 August 2014. Allied Minds, a research commercialization company in Boston, and the pharmaceutical company Bristol-Myers Squibb in New York are starting a joint venture to discover new drug candidates and enterprises from promising life science research in U.S. university labs. Financial terms of the new venture, named Allied-Bristol Life Sciences LLC, were not disclosed.…
-
Trial Shows Drug Not Extending Breast Cancer Survival Time
25 July 2014. A late-stage clinical trial of the cancer drug sorafenib shows the drug, combined with the chemotherapy drug capecitabine, does not extend the amount of progression-free survival time of advanced breast cancer patients, compared to capecitabine alone. Sorafenib, marketed under the brand name Nexavar, is made by Onyx Pharmaceuticals in South San Francisco,…
-
Zero-Gravity, Tropical Institute Partner on Food Security
24 July 2014. Zero Gravity Solutions Inc. and International Institute of Tropical Agriculture (IITA) are collaborating on implementing technologies originally developed for the U.S. space program to improve food security in Africa and other tropical regions. Financial terms of the agreement were not disclosed. IITA, in Ibadan, Nigeria, conducts research on agricultural plant health and…
-
Company, Institute Studying Youth Lung Cancer Genomes
23 July 2014. Foundation Medicine, a company providing genome-based personalized cancer diagnostics, and Addario Lung Cancer Medical Institute are studying the genomes of younger lung cancer patients to uncover differences in their cancer and identify therapies for this population. Financial terms of the collaboration were not disclosed. Some 224,000 people in the U.S. are expected…
-
Immunocore, Lilly Collaborate on T-Cell Cancer Therapies
16 July 2014. Drug maker Eli Lilly and Company in Indianapolis and Immunocore Ltd., a biotechnology company in Oxford, U.K. are jointly discovering new cancer therapies based on T-cells in the body’s immune system. The deal will pay Immunocore $15 million for each new therapy identified, with additional payments of $10 million for each therapy…
-
Geisinger, Indivumed Partner on Personalized Cancer Therapy
15 July 2014. Geisinger Health System that serves central and eastern Pennsylvania is partnering with Indivumed GmbH, a biotech company and biobank in Hamburg, Germany to provide individualized cancer diagnostics for Geisinger clients. Financial details of the deal first announced in May 2013, but formalized this week, were not disclosed. Indivumed maintains a biorepository of…